The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Shirley D’SaDuring the 12th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-12), the Lymphoma Hub was pleased to speak to Shirley D’Sa, University College London, London, UK. We asked about management of IgM demyelinating neuropathy in patients with Waldenstrom's macroglobulinemia (WM).
IWWM-12: Management of IgM demyelinating neuropathy in WM
In this interview, D’Sa discusses management of anti-myelin associated glycoprotein (MAG) neuropathy, a form of inflammatory neuropathy that impacts patients with IgM paraproteins. She highlights the efficacy of treatments, particularly the use of rituximab, while also acknowledging the complexities involved in determining the optimal timing for treatment and the metrics for assessing effectiveness. D’Sa emphasizes the importance of developing clinical metrics to effectively measure neuropathy and discusses the significance of a consensus panel aimed at enhancing treatment guidance for healthcare practitioners.
Your opinion matters
As a result of this content, I commit to reviewing the latest data from clinical trials of novel therapies for the treatment of Waldenstrom’s macroglobulinemia.
This educational resource is independently supported by BeiGene. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
